|
US4777127A
(en)
|
1985-09-30 |
1988-10-11 |
Labsystems Oy |
Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
|
|
GB8601597D0
(en)
|
1986-01-23 |
1986-02-26 |
Wilson R H |
Nucleotide sequences
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4704692A
(en)
|
1986-09-02 |
1987-11-03 |
Ladner Robert C |
Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
|
|
GB8702816D0
(en)
|
1987-02-07 |
1987-03-11 |
Al Sumidaie A M K |
Obtaining retrovirus-containing fraction
|
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
AP129A
(en)
|
1988-06-03 |
1991-04-17 |
Smithkline Biologicals S A |
Expression of retrovirus gag protein eukaryotic cells
|
|
WO1990007936A1
(en)
|
1989-01-23 |
1990-07-26 |
Chiron Corporation |
Recombinant therapies for infection and hyperproliferative disorders
|
|
AU648261B2
(en)
|
1989-08-18 |
1994-04-21 |
Novartis Vaccines And Diagnostics, Inc. |
Recombinant retroviruses delivering vector constructs to target cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
DE69233013T2
(de)
|
1991-08-20 |
2004-03-04 |
The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
WO1993010218A1
(en)
|
1991-11-14 |
1993-05-27 |
The United States Government As Represented By The Secretary Of The Department Of Health And Human Services |
Vectors including foreign genes and negative selective markers
|
|
GB9125623D0
(en)
|
1991-12-02 |
1992-01-29 |
Dynal As |
Cell modification
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
EP0650370A4
(en)
|
1992-06-08 |
1995-11-22 |
Univ California |
METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
|
|
CA2137361A1
(en)
|
1992-06-10 |
1993-12-23 |
W. French Anderson |
Vector particles resistant to inactivation by human serum
|
|
GB2269175A
(en)
|
1992-07-31 |
1994-02-02 |
Imperial College |
Retroviral vectors
|
|
EP1024198A3
(en)
|
1992-12-03 |
2002-05-29 |
Genzyme Corporation |
Pseudo-adenoviral vectors for the gene therapy of haemophiliae
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
EP0648835A1
(en)
|
1993-10-14 |
1995-04-19 |
The Procter & Gamble Company |
Use of alkaline polyammonium salts to increase cationic density in fabric softeners
|
|
AU687117B2
(en)
|
1993-10-25 |
1998-02-19 |
Canji, Inc. |
Recombinant adenoviral vector and methods of use
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5756910A
(en)
|
1996-08-28 |
1998-05-26 |
Burgett, Inc. |
Method and apparatus for actuating solenoids in a player piano
|
|
WO1998022588A2
(en)
|
1996-11-20 |
1998-05-28 |
Introgen Therapeutics, Inc. |
An improved method for the production and purification of adenoviral vectors
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
DK2211904T3
(en)
|
2007-10-19 |
2016-10-24 |
Seattle Genetics Inc |
Cd19-binding agents and uses thereof
|
|
MX2012004522A
(es)
|
2009-10-19 |
2012-05-08 |
Tristem Trading Cyprus Ltd |
Tratamiento que usa celulas adultas maduras reprogramadas.
|
|
SMT202000031T1
(it)
|
2010-06-09 |
2020-03-13 |
Genmab As |
Anticorpi contro cd38 umano
|
|
AU2011281062B2
(en)
|
2010-07-21 |
2015-01-22 |
Board Of Regents, The University Of Texas System |
Methods and compositions for modification of a HLA locus
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2655624B1
(en)
|
2010-12-23 |
2017-11-29 |
Biogen MA Inc. |
Linker peptides and polypeptides comprising same
|
|
US20130309223A1
(en)
|
2012-05-18 |
2013-11-21 |
Seattle Genetics, Inc. |
CD33 Antibodies And Use Of Same To Treat Cancer
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US20140310830A1
(en)
|
2012-12-12 |
2014-10-16 |
Feng Zhang |
CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
WO2014191128A1
(en)
|
2013-05-29 |
2014-12-04 |
Cellectis |
Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
|
|
EP3024485B1
(en)
|
2013-07-23 |
2020-11-18 |
Biocon Limited |
Use of a cd6 binding partner and method based thereon
|
|
EP2833591A1
(en)
|
2013-07-31 |
2015-02-04 |
Siemens Aktiengesellschaft |
Subsea data communication interface unit
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015121454A1
(en)
|
2014-02-14 |
2015-08-20 |
Cellectis |
Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
|
|
PL3119807T3
(pl)
|
2014-03-19 |
2019-09-30 |
Cellectis |
Specyficzne wobec cd123 chimeryczne receptory antygenowe do immunoterapii nowotworów
|
|
CN106795221B
(zh)
|
2014-04-03 |
2022-06-07 |
塞勒克提斯公司 |
用于癌症免疫治疗的cd33特异性嵌合抗原受体
|
|
WO2015157070A2
(en)
|
2014-04-09 |
2015-10-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
KR20200138445A
(ko)
|
2014-04-24 |
2020-12-09 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
|
|
WO2015195547A1
(en)
|
2014-06-16 |
2015-12-23 |
University Of Washington |
Methods for controlling stem cell potential and for gene editing in stem cells
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
SG10201913782UA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
|
DK3194570T3
(da)
|
2014-09-16 |
2021-09-13 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til nukleasemedieret genommodificering og -korrektion i hæmatopoietiske stamceller
|
|
KR101799975B1
(ko)
|
2014-10-31 |
2017-11-21 |
에스케이씨하이테크앤마케팅(유) |
액정표시장치용 색순도 향상 및 휘도 보상 필름 및 이를 포함하는 액정표시장치
|
|
US10201606B2
(en)
|
2014-11-26 |
2019-02-12 |
Miltenyi Biotec Gmbh |
Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
|
|
CA2969619A1
(en)
|
2014-12-03 |
2016-06-09 |
Agilent Technologies, Inc. |
Guide rna with chemical modifications
|
|
CN107406506A
(zh)
|
2014-12-04 |
2017-11-28 |
詹森生物科技公司 |
用于治疗急性髓系白血病的抗cd38抗体
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
BR112017013981A2
(pt)
|
2015-01-26 |
2018-01-02 |
Cellectis |
receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
|
|
KR102888521B1
(ko)
|
2015-04-06 |
2025-11-19 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
Crispr/cas-매개 유전자 조절을 위한 화학적으로 변형된 가이드 rna
|
|
JP6961490B2
(ja)
*
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
CN108064176A
(zh)
|
2015-04-22 |
2018-05-22 |
库瑞瓦格股份公司 |
用于治疗肿瘤疾病的含有rna的组合物
|
|
GB201507119D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
EP3288569A4
(en)
|
2015-04-29 |
2018-12-19 |
Fred Hutchinson Cancer Research Center |
Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
|
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
CN108026526B
(zh)
|
2015-06-09 |
2023-05-12 |
爱迪塔斯医药公司 |
用于改善移植的crispr/cas相关方法和组合物
|
|
US10501545B2
(en)
|
2015-06-16 |
2019-12-10 |
Genentech, Inc. |
Anti-CLL-1 antibodies and methods of use
|
|
WO2017025323A1
(en)
|
2015-08-11 |
2017-02-16 |
Cellectis |
Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
|
|
AU2016337525B2
(en)
|
2015-10-16 |
2022-01-20 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for inhibition of lineage specific antigens
|
|
IL310721B2
(en)
|
2015-10-23 |
2025-11-01 |
Harvard College |
Nucleobase editors and uses thereof
|
|
WO2017079400A1
(en)
|
2015-11-04 |
2017-05-11 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for gene editing in hematopoietic stem cells
|
|
HK1258375A1
(zh)
|
2015-11-24 |
2019-11-08 |
Onk Therapeutics Limited |
人源化抗-cll-1抗体
|
|
KR20230148844A
(ko)
|
2016-03-29 |
2023-10-25 |
유니버시티 오브 써던 캘리포니아 |
암을 표적하는 키메라 항원 수용체
|
|
US11499168B2
(en)
|
2016-04-25 |
2022-11-15 |
Universitat Basel |
Allele editing and applications thereof
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
CA3025667A1
(en)
|
2016-06-08 |
2017-12-14 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
CN109562126A
(zh)
|
2016-06-24 |
2019-04-02 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(car)、组合物及其使用方法
|
|
AU2017291851B2
(en)
|
2016-07-06 |
2022-10-13 |
Cellectis |
Sequential gene editing in primary immune cells
|
|
SI3529262T1
(sl)
|
2016-10-21 |
2021-12-31 |
Inserm - Institut National De La Sante Et De La Recherche Medicale |
Postopki za spodbujanje odgovora T-celic
|
|
LT3535392T
(lt)
|
2016-11-02 |
2024-04-25 |
Universität Basel |
Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
|
|
CA3048434A1
(en)
|
2016-12-30 |
2018-07-05 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
RU2019130504A
(ru)
*
|
2017-02-28 |
2021-03-30 |
Вор Байофарма, Инк. |
Композиции и способы ингибирования линиеспецифических белков
|
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
EA201992546A1
(ru)
|
2017-04-24 |
2020-03-06 |
Мемориал Слоан Кеттеринг Кэнсер Сентер |
Средства на основе антител к cd33
|
|
CA3064000A1
(en)
|
2017-05-24 |
2018-11-29 |
Effector Therapeutics, Inc. |
Methods and compositions for cellular immunotherapy
|
|
US11718659B2
(en)
|
2017-08-28 |
2023-08-08 |
The Trustees Of Columbia University In The City Of New York |
CD33 exon 2 deficient donor stem cells for use with CD33 targeting agents
|
|
EP3746554A1
(en)
|
2018-01-30 |
2020-12-09 |
Editas Medicine, Inc. |
Systems and methods for modulating chromosomal rearrangements
|
|
CN111699254A
(zh)
|
2018-02-08 |
2020-09-22 |
齐默尔根公司 |
使用crispr在棒状杆菌属中进行基因组编辑
|
|
TWI669677B
(zh)
|
2018-03-07 |
2019-08-21 |
光陽工業股份有限公司 |
充電座管理方法、用於充電座管理方法的伺服器及充電座
|
|
KR102817092B1
(ko)
|
2018-03-29 |
2025-06-09 |
페이트 세러퓨틱스, 인코포레이티드 |
조작된 면역 효과기 세포 및 이의 용도
|
|
WO2020028533A1
(en)
|
2018-08-01 |
2020-02-06 |
Yale University |
Compositions and methods for identification of membrane targets for enhancement of t cell activity against cancer
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
BR112021008041A2
(pt)
*
|
2018-11-07 |
2021-08-10 |
Crispr Therapeutics Ag |
terapia contra o câncer com células imunitárias anti-cd33
|
|
EP3911735A4
(en)
|
2019-01-16 |
2023-07-12 |
Beam Therapeutics, Inc. |
MODIFIED IMMUNE CELLS WITH INCREASED ANTINEOPLASTIC ACTIVITY AND RESISTANCE TO IMMUNOSUPPRESSION
|
|
BR112021014010A2
(pt)
|
2019-01-16 |
2021-09-21 |
The Trustees Of Columbia University In The City Of New York |
Composições e métodos para inibição de antígenos linhagem-específicos
|
|
CN120174005A
(zh)
|
2019-02-13 |
2025-06-20 |
比姆医疗股份有限公司 |
具有用于修饰靶标序列中核碱基的腺苷脱氨酶碱基编辑器的经修饰的免疫细胞
|
|
AU2020280103A1
(en)
*
|
2019-05-23 |
2021-12-23 |
Vor Biopharma Inc. |
Compositions and methods for CD33 modification
|
|
EA202191979A1
(ru)
|
2019-05-24 |
2021-11-01 |
Зе Трастис Оф Коламбия Юниверсити Ин Зе Сити Оф Нью-Йорк |
Композиции и способы ингибирования линиеспецифических антигенов
|
|
EP3987087A4
(en)
|
2019-06-21 |
2023-11-15 |
Function Oncology, Inc. |
GENETIC PHARMACEOPIA FOR COMPREHENSIVE FUNCTIONAL PROFILING OF HUMAN CANCERS
|
|
AU2020338011A1
(en)
|
2019-08-28 |
2022-03-10 |
Vor Biopharma Inc. |
Compositions and methods for CLL1 modification
|
|
WO2021041977A1
(en)
|
2019-08-28 |
2021-03-04 |
Vor Biopharma, Inc. |
Compositions and methods for cd123 modification
|
|
WO2022047168A1
(en)
|
2020-08-28 |
2022-03-03 |
Vor Biopharma Inc. |
Compositions and methods for cll1 modification
|
|
JP2023541457A
(ja)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
Ｃｄ３８修飾のための化合物および方法
|
|
US20230364233A1
(en)
|
2020-09-28 |
2023-11-16 |
Vor Biopharma Inc. |
Compositions and methods for cd6 modification
|
|
JP2024502820A
(ja)
*
|
2020-12-31 |
2024-01-23 |
ブイオーアール バイオファーマ インコーポレーテッド |
Ｃｄ３４遺伝子改変のための組成物及び方法
|
|
WO2023043858A1
(en)
*
|
2021-09-14 |
2023-03-23 |
Vor Biopharma Inc. |
Compositions and methods for multiplex base editing in hematopoietic cells
|
|
EP4433512A4
(en)
|
2021-11-19 |
2025-12-31 |
Univ Pennsylvania |
Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy
|
|
AU2022422572A1
(en)
|
2021-12-23 |
2024-06-06 |
Cimeio Therapeutics Ag |
Discernible cell surface protein variants of cd45 for use in cell therapy
|
|
JP2025508721A
(ja)
|
2022-02-18 |
2025-04-10 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
細胞表面受容体のエピトープ操作
|